Wednesday, 18 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:11 PM ET 8-K
Leadership Change Fortune Brands Innovations, Inc. FBIN

Fortune Brands Innovations Leadership Change

Fortune Brands Innovations elected Victor Grizzle to its Board of Directors effective January 1, 2027, while announcing the upcoming retirements of longtime directors David Mackay and Ann Fritz Hackett. Mr. Grizzle, currently Executive Chair of Armstrong World Industries, will serve on the Nominating and Governance and Compensation Committees. These changes are part of a planned board refreshment process as the company transitions its leadership team.

Counterparty
Victor Grizzle
4:11 PM ET 8-K
Clinical Trial Data Attovia Therapeutics, Inc. ATTO

Attovia Therapeutics Clinical Trial Data

Attovia Therapeutics announced positive topline 12-week results from its Phase 1b study of ATTO-1310 in patients with chronic pruritus and high-itch atopic dermatitis. The data showed rapid and sustained itch relief with 82% of chronic pruritus patients achieving a clinically meaningful reduction in itch at Week 12, supporting the potential for quarterly maintenance dosing.

“The recently announced 12-week topline results from our ATTO-1310 Phase 1b trial exceeded our expectations, building on the compelling Week 4 findings and providing further evidence supporting our differentiated target product profile: rapid, deep, and durable itch relief, meaningful skin lesion improvements, the potential for quarterly dosing, and a favorable safety profile.”

Tao Fu, Founder and Chief Executive Officer of Attovia
4:11 PM ET 8-K
Financial Results Paradium.AI, Inc. PAAI

Paradium.AI Financial Results

Paradium.AI reported Q3 2026 revenue of $20.5 million, a 31.2% decline year-over-year driven by lower referral traffic from platforms like Google Discover. The company posted a net loss of $3.8 million compared to net income in the prior year, as it continues a strategic shift toward AI-powered monetization and content tools to reduce dependence on external traffic sources.

Term
Q3 2026

“We continue to see tremendous opportunity in the age of AI, and we’re all in. While retaining referral traffic remains part of our focus, our real momentum is powered by tools like Cutter Studios and InfoSentience, which are already increasing output and efficiency.”

Paul Edmondson, CEO of Paradium.AI
4:11 PM ET 8-K
Financial Results Definium Therapeutics, Inc. DFTX

Definium Therapeutics Financial Results

Definium Therapeutics reported Q3 2026 financial results, highlighting a strong cash position of $1.05 billion. The company achieved positive Phase 3 topline results for DT120 ODT in generalized anxiety disorder and received FDA Breakthrough Therapy Designation for the same candidate in major depressive disorder.

Term
Q3 2026

“Our positive Phase 3 topline results from Voyage and Panorama this quarter further strengthened the evidence supporting DT120 ODT. Together with our previously reported results, these findings demonstrate consistent, clinically meaningful results across three Phase 3 studies in GAD and MDD, reinforcing our confidence in DT120 ODT’s potential to address significant unmet needs across both conditions.”

Rob Barrow, Chief Executive Officer

“With Breakthrough Therapy designation in MDD and Ascend progressing, we continue to advance our late-stage program while building the capabilities needed to prepare for potential approval and commercialization. Beyond DT120, we believe DT402 represents an exciting opportunity and its initial results support continued development as we work to deliver differentiated therapies for patients with significant unmet needs.”

Rob Barrow, Chief Executive Officer
4:11 PM ET 10-Q
Financial Results StepStone Group Inc. STEP

StepStone Group Q2 2026 Results: Net Loss of $71.2M, Loss Narrows

StepStone Group Inc. reported total assets of $9.26 billion as of September 30, 2026, a significant increase from $6.76 billion in March 2026, primarily driven by growth in investments and assets of consolidated funds. The company remains a large accelerated filer with 82,475,390 shares of Class A common stock outstanding as of November 3, 2026.

Key figure
Net loss $71.2M
4:10 PM ET 10-Q
Financial Results Editas Medicine, Inc. EDIT

Editas Medicine Q3 2026 Results: Net Loss of $23.4M, Loss Narrows

Editas Medicine reported a net loss of $23.4 million for the third quarter of 2026, a significant improvement from the $154.4 million loss in the prior year period which was impacted by restructuring charges. The company strengthened its balance sheet through a $116.9 million common stock and warrant financing, ending the period with $190.2 million in cash, cash equivalents, and marketable securities.

Key figure
Net loss $23.4M
4:10 PM ET 10-Q
Financial Results Zymeworks Inc. ZYME

Zymeworks Q3 2026 Results: Turns Profitable, Net Income $174M

Zymeworks Inc. reported a significant increase in total revenue to $256.5 million for the third quarter of 2026, primarily driven by $250.0 million in license and milestone revenue. The company achieved a net income of $173.7 million for the quarter, a substantial improvement from the $19.6 million net loss in the prior year period, despite an increase in operating expenses to $78.9 million.

Key figure
Net income $174M
4:10 PM ET 8-K
Financial Results Ethan Allen Interiors Inc ETD

Ethan Allen Interiors Financial Results

Ethan Allen reported fiscal 2027 first quarter results with consolidated net sales of $129.6 million, down from $147.0 million in the prior year. The company's margins were pressured by lower sales volumes and new Section 301 tariffs, though it maintained a strong cash position of $92.2 million with no debt. Despite a soft housing market, retail written orders showed sequential momentum, rising 13.2% compared to the previous quarter.

Term
Q1 2027
4:10 PM ET 8-K
Financial Results Trade Desk, Inc. TTD

Trade Desk Financial Results

The Trade Desk reported Q3 2026 revenue of $736 million and GAAP net income of $38 million, while also announcing a $731 million increase to its share repurchase program. CEO Jeff Green noted that while results exceeded expectations, the company is moving with greater urgency to improve its growth trajectory through platform innovations like Zuma and agentic AI.

“Q3 represented meaningful progress, with results well ahead of our expectations entering the quarter, but we are still operating below the level of growth we expect from ourselves. We are moving with greater urgency across the company, strengthening how we engage with our largest customers, improving the platform through innovations such as Zuma, Audience Unlimited, agentic AI, and advancing a new approach to measurement designed to help marketers better understand what is actually driving business growth. We have more work to do, but I believe the actions we are taking are improving the underlying trajectory of the business and positioning The Trade Desk for stronger, more durable growth over the long term.”

Jeff Green, Co-Founder and CEO of The Trade Desk
4:10 PM ET 8-K
Financial Results Maze Therapeutics, Inc. MAZE

Maze Therapeutics Financial Results

Maze Therapeutics reported third quarter 2026 financial results, ending the period with $477 million in cash and a projected runway into 2029. The company highlighted the completion of enrollment for its Phase 2 HORIZON trial of MZE829 in APOL1-mediated kidney disease, with data expected in early 2027. Net loss for the quarter was $38.4 million, driven by increased R&D expenses related to its clinical-stage pipeline.

Term
Q3 2026

“Completing enrollment in HORIZON with more than 50 patients across three cohorts marks an important milestone for MZE829 and exceeded our target enrollment of 10-15 patients per cohort. HORIZON gives us the opportunity to generate a robust dataset across three distinct AMKD patient populations, including patients with and without diabetes and those with FSGS, and provide a comprehensive view of MZE829’s potential as a best-in-class therapy for a broad AMKD population, supported by its differentiated dual mechanism of action.”

Jason Coloma, Ph.D., chief executive officer of Maze
4:10 PM ET 8-K
Financial Results Octave Specialty Group Inc OSG

Octave Specialty Group Financial Results

Octave Specialty Group reported third quarter 2026 financial results, highlighted by a 28% increase in total revenue to $85.3 million. The company's Insurance Distribution segment saw 35% revenue growth, while the Specialty P&C Insurance segment (Everspan) returned to profitability with $1.3 million in net income.

Term
Q3 2026

“Octave delivered a solid third quarter, with continued growth in our Insurance Distribution business and further progress at Everspan, despite a P&C market that has become more competitive as the year has progressed. While we expect market softening to continue into 2027, we believe that our operating model was built to perform through market cycles, and Octave is well positioned to deliver sustained, profitable growth toward our long-term goals.”

Claude LeBlanc, President and Chief Executive Officer

“In the third quarter, we grew our Insurance Distribution revenue 35%, including organic revenue growth of 23%. This strong organic growth, well ahead of the broader industry, is consistent with our seasonally adjusted third quarter plan and reflects the strength of our purposely diversified portfolio strategy and the strong embedded value of our scaling MGA incubator.”

Claude LeBlanc, President and Chief Executive Officer
4:10 PM ET 10-Q
Financial Results Gladstone Investment Corporation\De GAIN ▶ Call

Gladstone Investment Corporation\De Q2 2026 Results: Net Income $17.1M, Down 40.6% YoY

For the six months ended September 30, 2026, Gladstone Investment Corporation reported total investment income of $52.5 million and net investment income of $20.8 million. Net assets decreased from $668.2 million at the start of the fiscal year to $654.3 million, primarily due to $19.1 million in distributions and $15.6 million in net realized and unrealized losses.

Key figure
Net income $17.1M · -40.6% YoY
4:10 PM ET 8-K
Financial Results Aaon, Inc. AAON

Aaon Financial Results

AAON reported record Q3 2026 net sales of $707.4 million, an 84.1% increase year-over-year, while raising its full-year outlook. Concurrently, the company announced a restatement of its Q1 and Q2 2026 financial statements due to revenue calculation errors and identified a material weakness in internal controls.

Term
Q3 2026

“Our third quarter results reflect strong execution and continued progress turning the investments we have made into stronger operating performance. We delivered record net sales, more than doubled operating income and diluted EPS, improved gross margin 60 basis points sequentially, generated strong cash flow and raised full-year outlook.”

Matt Tobolski, President and CEO of The Aaon Group

“During our third quarter reporting process, we also identified errors in our previously reported first and second quarter financial statements. We corrected those errors and determined that a material weakness existed in our internal control over financial reporting. We take that seriously.”

Matt Tobolski, President and CEO of The Aaon Group
4:10 PM ET Form 4
Insider Buying Autonation, Inc. AN

Autonation EVP & CFO Thomas A. Szlosek Buys $200K of Stock

Thomas A. Szlosek, EVP & CFO, bought 1,081 shares of Autonation, Inc. at $184.56 to $185.10 a share (average $184.83) in 2 transactions, worth $200K in total between Nov 5, 2026 and Nov 6, 2026. Shares held after the trade: 21,166 (+2.6%).

Value
$200K
Shares
1,081
Average price
$184.83
Role
EVP & CFO
Holding change
+2.6%
Trade date
Nov 5, 2026 to Nov 6, 2026
4:10 PM ET 8-K
Financial Results Zentalis Pharmaceuticals, Inc. ZNTL

Zentalis Pharmaceuticals Financial Results

Zentalis Pharmaceuticals reported third quarter 2026 financial results and provided updates on its clinical pipeline, specifically the azenosertib program for ovarian cancer. The company expects a topline readout from the DENALI trial in the first half of 2027 and reported a cash runway extending into the first half of 2028.

“Overall survival data from DENALI Part 1b presented at ESMO reinforce our confidence in azenosertib to offer a differentiated oral treatment for patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC), if approved.”

Julie Eastland, Chief Executive Officer of Zentalis Pharmaceuticals

“With $228.9 million on the balance sheet providing an anticipated runway into the first half of 2028, we believe we are well resourced to support key DENALI milestones, full enrollment in ASPENOVA and combination trials in ovarian cancer and triple-negative breast cancer.”

Julie Eastland, Chief Executive Officer of Zentalis Pharmaceuticals
4:10 PM ET 8-K
Financial Results Quantum Computing Inc. QUBT

Quantum Computing Financial Results

Quantum Computing Inc. reported Q3 2026 revenue of $9.5 million, a significant increase from $384 thousand in the prior year, driven by recent acquisitions of LSI, NuCrypt, and NHanced. The company reported a net loss of $15.1 million for the quarter while maintaining a strong liquidity position with approximately $1.3 billion in cash and investments.

Term
Q3 2026

“For several years, we've been building the technology and capabilities to make quantum more practical and accessible. We're starting to see those investments come together, and our focus is increasingly shifting from what we can build to what we can put to work for customers. We're encouraged by our progress, but recognize there's considerable work ahead. Our priorities are clear: growing our commercial business, scaling manufacturing and advancing our quantum roadmap. I've always believed that being early creates opportunity. Execution is what makes that opportunity last.”

Dr. Yuping Huang, Chief Executive Officer of QCi
4:10 PM ET 8-K
Financial Results Orasure Technologies Inc OSUR

Orasure Technologies Financial Results

OraSure Technologies reported Q3 2026 financial results with 14% year-over-year revenue growth to $30.9 million, driven by its core business strategy. The company saw GAAP gross margin expansion to 45.2% and received initial orders for its newly launched Colli-Pee Dx and OraQuick Ebola 2.0 products.

Term
Q3 2026

“Our third quarter results demonstrate the continued execution of our strategy. In addition to delivering double-digit year-over-year revenue growth, we meaningfully expanded gross margins and benefited from operational efficiency initiatives that reduced our cost base.”

Carrie Eglinton Manner, President and CEO

“Looking ahead to the fourth quarter and into 2027, we believe we are well positioned for continued revenue growth. Supported by a robust balance sheet, we will continue to invest behind initiatives to accelerate topline growth, improve our operating model, and drive towards profitability.”

Carrie Eglinton Manner, President and CEO
4:10 PM ET 8-K
Business Update National Health Investors Inc NHI

National Health Investors Business Update

National Health Investors (NHI) furnished its supplemental information package for the third quarter ended September 30, 2026. The document provides operational metrics and portfolio overviews, including senior housing operating portfolio performance and lease coverage data. This filing serves as a Regulation FD disclosure of non-GAAP and operational data rather than a formal GAAP earnings release.

4:10 PM ET 8-K
Business Update Larimar Therapeutics, Inc. LRMR

Larimar Therapeutics Business Update

Larimar Therapeutics has completed its rolling Biologics License Application (BLA) submission to the FDA seeking accelerated approval for nomlabofusp in Friedreich’s ataxia. The filing also includes a preliminary cash balance of $128.7 million as of September 30, 2026, and an updated corporate presentation for investor meetings.

Counterparty
FDA
4:10 PM ET 8-K
Financial Results Ameresco, Inc. AMRC

Ameresco Financial Results

Ameresco reported third-quarter 2026 financial results with revenue growth of 10% to $580.3 million and a record total backlog of $7.2 billion. The company saw strong momentum in its Federal and European business lines, including $200 million in new data center energy infrastructure awards.

Term
Q3 2026

“Our third quarter results represented another quarter of strong growth and disciplined execution. We achieved revenue increases across each of our major business lines, expanded margins and continued to build both awarded and contracted backlogs.”

George Sakellaris, CEO

“The strength of our business model is reflected in the diversity of our solutions, markets and customers. We secured over $675 million in additional awards driven by strength in Federal infrastructure and Europe.”

George Sakellaris, CEO
4:10 PM ET 10-Q
Financial Results Brighthouse Life Insurance Co

Brighthouse Life Insurance Q3 2026 Results: Net Income $267M, Down 29.9% YoY

For the nine months ended September 30, 2026, Brighthouse Life Insurance Company reported net income of $445 million, a significant increase from $161 million in the prior year period. However, the company experienced a substantial decrease in total stockholder's equity from $8.08 billion at year-end 2025 to $6.37 billion, primarily driven by $2.16 billion in other comprehensive losses.

Key figure
Net income $267M · -29.9% YoY
4:10 PM ET 10-Q
Financial Results Crescent Capital BDC, Inc. CCAP

Crescent Capital BDC Q3 2026 Results: Net Income $10.1M, Up 42.4% YoY

Crescent Capital BDC, Inc. reported total investment income of $111.1 million for the nine months ended September 30, 2026, a decrease from $126.5 million in the prior year period. Net asset value per share declined to $17.72 from $19.10 at year-end 2025, while net investment income for the first nine months of 2026 was $42.3 million.

Key figure
Net income $10.1M · +42.4% YoY
4:09 PM ET 8-K
Financial Results National Health Investors Inc NHI

National Health Investors Financial Results

National Health Investors reported Q3 2026 financial results, highlighted by a significant increase in net income to $11.47 per diluted share, primarily driven by a $541.6 million gain from the sale of the NHC leased portfolio. The company has closed over $395 million in investments year-to-date and expects to complete additional acquisitions before year-end to drive SHOP segment growth.

Term
Q3 2026

“SHOP and private-pay senior housing remain central to our long-term growth strategy, and we have invested in our executive management team to strengthen operating execution and improve portfolio performance.”

Eric Mendelsohn, NHI’s President and CEO

“We have closed more than $395 million in investments year-to-date and expect to complete significant additional investments before year-end, with ample capital available to fund our current pipeline.”

Eric Mendelsohn, NHI’s President and CEO
4:09 PM ET 10-Q
Financial Results Nerdy Inc. NRDY

Nerdy Q3 2026 Results: Net Loss of $8.59M, Loss Narrows

Nerdy Inc. reported a decrease in revenue to $33.2 million for the third quarter of 2026, down from $37.0 million in the prior year period. Despite the revenue decline, the company narrowed its quarterly net loss to $12.8 million compared to $18.8 million in Q3 2025, driven by significant reductions in sales, marketing, and general administrative expenses.

Key figure
Net loss $8.59M
4:09 PM ET 8-K
Financial Results Lucid Group, Inc. LCID

Lucid Group Financial Results

Lucid Group reported Q3 2026 revenue of $350 million, a 4% year-over-year increase despite a broader market decline. The company reduced quarterly cash consumption by 30% sequentially and secured an additional $1.75 billion in liquidity from the Public Investment Fund (PIF) to fund operations into late 2027.

Term
Q3 2026

“Our transformation is beginning to show progress. We are acting with urgency, strengthening the fundamentals and driving greater discipline, while continuing to invest in the priorities to deliver profitable long-term growth.”

Silvio Napoli, Chief Executive Officer

“The operating reset announced with our Q2 results includes decisive actions to align our manufacturing capacity with demand, reduce inventory and lower operating expenses. These actions are already showing through in Q3, with free cash flow consumption 30% lower sequentially.”

Alexander De Bock, Chief Financial Officer
4:09 PM ET 8-K
Financial Results Ziprecruiter, Inc. ZIP

Ziprecruiter Financial Results

ZipRecruiter reported Q3 2026 financial results with revenue of $124.4 million and net income of $5.1 million, exceeding the high end of its previous guidance. CEO Ian Siegel noted that product improvements and AI-driven marketplace engagement reached all-time highs despite a flat broader hiring environment.

Term
Q3 2026

“ZipRecruiter’s momentum continued to accelerate in the third quarter as we grew revenue and expanded profitability year-over-year. In the third quarter, both revenue and Adjusted EBITDA came in above the high end of our guidance range, and our updated full-year 2026 outlook reflects stronger than expected growth and profitability.”

Ian Siegel, CEO of ZipRecruiter

“As AI reshapes how people look for work, we are betting the platform that wins will be the one that delivers human-to-human connections for both job seekers and employers. That vision defines our roadmap, and we believe we are just getting started.”

Ian Siegel, CEO of ZipRecruiter
4:09 PM ET 8-K
Financial Results Baldwin Insurance Group, Inc. BWIN

Baldwin Insurance Group Financial Results

The Baldwin Insurance Group reported Q3 2026 financial results with total revenue growth of 31% to $480.3 million and Adjusted EBITDA growth of 47% to $106.9 million. The company also provided an update on its pending all-cash take-private merger with Sequence AI Holdings and DFO Management for $32.50 per share, which is expected to close in Q1 2027.

Term
Q3 2026
4:09 PM ET 10-Q
Financial Results SS&C Technologies Holdings Inc SSNC

SS&C Technologies Holdings Q3 2026 Results: Net Income $199M, Down 5.3% YoY

SS&C Technologies reported total revenues of $5,032.8 million for the nine months ended September 30, 2026, representing a 9.0% increase over the prior year. Net income attributable to common stockholders rose to $659.8 million, while the company significantly increased its treasury stock purchases to $760.5 million during the period.

Key figure
Net income $199M · -5.3% YoY
4:09 PM ET 10-Q
Financial Results Annexon, Inc. ANNX

Annexon Q3 2026 Results: Net Loss of $51.2M, Loss Narrows

Annexon, Inc. reported a net loss of $150.7 million for the nine months ended September 30, 2026, compared to $158.4 million in the prior year period. The company strengthened its balance sheet through a $49.3 million term loan and common stock issuances, ending the period with $213.4 million in cash, cash equivalents, and short-term investments.

Key figure
Net loss $51.2M
4:09 PM ET 8-K
Financial Results Qualys, Inc. QLYS

Qualys Financial Results

Qualys reported Q3 2026 revenue of $188.0 million, an 11% increase year-over-year, and GAAP net income of $57.2 million. The company raised its full-year 2026 revenue guidance to a range of $736.9 million to $738.9 million, citing strong adoption of its AI-native Risk Operations Center.

Term
Q3 2026

“In Q3, we delivered another quarter of strong revenue growth and profitability. Increasing adoption of our AI-native Risk Operations Center, driven by our partner-first strategy, reflects accelerating demand for a vendor-neutral platform that actually fixes security issues rather than just reporting them. These results distinguish our competitive position in pre-breach risk management and reinforce our confidence in long-term growth.”

Sumedh Thakar, Qualys president and CEO

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.